Update COVID-19 Pandemic
At Vivoryon, our primary concern remains to ensure our employees and their families are safe as we continue moving operations forward to the best of our abilities. We are monitoring the evolving situation closely and will provide updates should the pandemic have any material effects on our business operations or clinical trials.
first-in-class clinical phase 2 molecule in Alzheimer’s disease
clinical phase 1/2 ready first-in-class molecule for cancer immune checkpoint inhibition
patent families around QPCT and QPCTL inhibitors
track-record of bringing drugs from research into clinic
in vivo characterized small molecule inhibitors for cancer immune checkpoint inhibition
family of diabetes blockbuster drugs based on our research